Treatment options for nonalcoholic steatohepatitis (NASH) are limited: gastric reduction surgery for the morbidly obese and weight loss for those who can achieve it. A third option may be the use of medications for treatment of type 2 diabetes mellitus and insulin resistance syndromes, suggest researchers in two small studies presented here in a poster session at the 53rd Annual Meeting of the American Association for the Study of Liver Diseases.
In a pilot study of the lipoprotein lipase inhibitor orlistat (Xenical) in obese patients with confirmed NASH, Stephen A. Harrison, MD, and colleagues from the Brooke Army Medical Center and Wilford Hall Medical Center in San Antonio, Texas, found that the combination of drug and dietary counseling was associated with significant decreases in body weight, glycohemoglobin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Six patients had normalization of transaminases, and histopathology studies showed “obvious steatosis improvement and mild decreased inflammation or fibrosis in some,” the authors write in their study abstract.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!